

RealRate

PHARMACEUTICAL 2020



GERON CORP Rank 87 of 358







RealRate

PHARMACEUTICAL 2020

GERON CORP Rank 87 of 358



The relative strengths and weaknesses of GERON CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of GERON CORP compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 73% points. The greatest weakness of GERON CORP is the variable Other Revenues, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 173%, being 137% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	141,608
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	28,162
Liabilities, Non-Current	0
Other Assets	23,501
Other Compr. Net Income	315
Other Expenses	69
Other Liabilities	0
Other Net Income	-195
Other Revenues	4,681
Property and Equipment	408
Research and Development	52,072
Selling, General and Administrative Expense	20,893

Output Variable	Value in 1000 USD
Assets	165,517
Liabilities	28,162
Expenses	73,034
Revenues	4,681
Stockholders Equity	137,355
Net Income	-68,548
Comprehensive Net Income	-68,390
Economic Capital Ratio	173%

